These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
718 related articles for article (PubMed ID: 17617523)
1. Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2. Kauff ND; Barakat RR J Clin Oncol; 2007 Jul; 25(20):2921-7. PubMed ID: 17617523 [TBL] [Abstract][Full Text] [Related]
2. Ovarian pathology in risk-reducing salpingo-oophorectomies from women with BRCA mutations, emphasizing the differential diagnosis of occult primary and metastatic carcinoma. Rabban JT; Barnes M; Chen LM; Powell CB; Crawford B; Zaloudek CJ Am J Surg Pathol; 2009 Aug; 33(8):1125-36. PubMed ID: 19440148 [TBL] [Abstract][Full Text] [Related]
3. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. Kauff ND; Satagopan JM; Robson ME; Scheuer L; Hensley M; Hudis CA; Ellis NA; Boyd J; Borgen PI; Barakat RR; Norton L; Castiel M; Nafa K; Offit K N Engl J Med; 2002 May; 346(21):1609-15. PubMed ID: 12023992 [TBL] [Abstract][Full Text] [Related]
4. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations. Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145 [TBL] [Abstract][Full Text] [Related]
5. Transitional cell metaplasia of fallopian tube fimbriae: a potential mimic of early tubal carcinoma in risk reduction salpingo-oophorectomies from women With BRCA mutations. Rabban JT; Crawford B; Chen LM; Powell CB; Zaloudek CJ Am J Surg Pathol; 2009 Jan; 33(1):111-9. PubMed ID: 18830124 [TBL] [Abstract][Full Text] [Related]
6. Multistep level sections to detect occult fallopian tube carcinoma in risk-reducing salpingo-oophorectomies from women with BRCA mutations: implications for defining an optimal specimen dissection protocol. Rabban JT; Krasik E; Chen LM; Powell CB; Crawford B; Zaloudek CJ Am J Surg Pathol; 2009 Dec; 33(12):1878-85. PubMed ID: 19898224 [TBL] [Abstract][Full Text] [Related]
7. Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy. Lamb JD; Garcia RL; Goff BA; Paley PJ; Swisher EM Am J Obstet Gynecol; 2006 Jun; 194(6):1702-9. PubMed ID: 16731090 [TBL] [Abstract][Full Text] [Related]
8. Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families. Giannini G; Capalbo C; Ristori E; Ricevuto E; Sidoni T; Buffone A; Cortesi E; Marchetti P; Scambia G; Tomao S; Rinaldi C; Zani M; Ferraro S; Frati L; Screpanti I; Gulino A Breast Cancer Res Treat; 2006 Nov; 100(1):83-91. PubMed ID: 16847550 [TBL] [Abstract][Full Text] [Related]
9. Twenty-three novel BRCA1 and BRCA2 sequence alterations in breast and/or ovarian cancer families in Southern Germany. Meyer P; Voigtlaender T; Bartram CR; Klaes R Hum Mutat; 2003 Sep; 22(3):259. PubMed ID: 12938098 [TBL] [Abstract][Full Text] [Related]
10. Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy. Powell CB; Kenley E; Chen LM; Crawford B; McLennan J; Zaloudek C; Komaromy M; Beattie M; Ziegler J J Clin Oncol; 2005 Jan; 23(1):127-32. PubMed ID: 15625367 [TBL] [Abstract][Full Text] [Related]
11. Germline mutations of BRCA1 and BRCA2 in Korean breast and/or ovarian cancer families. Kang HC; Kim IJ; Park JH; Kwon HJ; Won YJ; Heo SC; Lee SY; Kim KH; Shin Y; Noh DY; Yang DH; Choe KJ; Lee BH; King SB; Park JG Hum Mutat; 2002 Sep; 20(3):235. PubMed ID: 12204006 [TBL] [Abstract][Full Text] [Related]
12. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study. Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443 [TBL] [Abstract][Full Text] [Related]
13. A controlled study of mental distress and somatic complaints after risk-reducing salpingo-oophorectomy in women at risk for hereditary breast ovarian cancer. Michelsen TM; Dørum A; Dahl AA Gynecol Oncol; 2009 Apr; 113(1):128-33. PubMed ID: 19178933 [TBL] [Abstract][Full Text] [Related]
14. Single-port risk-reducing salpingo-oophorectomy with and without hysterectomy: surgical outcomes and learning curve analysis. Escobar PF; Starks DC; Fader AN; Barber M; Rojas-Espalliat L Gynecol Oncol; 2010 Oct; 119(1):43-7. PubMed ID: 20579712 [TBL] [Abstract][Full Text] [Related]
15. Novel germline BRCA1 and BRCA2 mutations in Turkish women with breast and/or ovarian cancer and their relatives. Egeli U; Cecener G; Tunca B; Tasdelen I Cancer Invest; 2006; 24(5):484-91. PubMed ID: 16939956 [TBL] [Abstract][Full Text] [Related]
16. The predominant role of surgery in the prevention and new trends in the surgical treatment of women with BRCA1/2 mutations. Fatouros M; Baltoyiannis G; Roukos DH Ann Surg Oncol; 2008 Jan; 15(1):21-33. PubMed ID: 17940826 [TBL] [Abstract][Full Text] [Related]
17. Novel germline BRCA1 and BRCA2 mutations in breast and breast/ovarian cancer families from the Czech Republic. Machackova E; Damborsky J; Valik D; Foretova L Hum Mutat; 2001 Dec; 18(6):545. PubMed ID: 11748848 [TBL] [Abstract][Full Text] [Related]
18. Prophylactic oophorectomy in women at increased cancer risk. Domchek SM; Rebbeck TR Curr Opin Obstet Gynecol; 2007 Feb; 19(1):27-30. PubMed ID: 17218848 [TBL] [Abstract][Full Text] [Related]
19. Short-term surgical outcome and safety of risk reducing salpingo-oophorectomy in BRCA1/2 mutation carriers. Kenkhuis MJ; de Bock GH; Elferink PO; Arts HJ; Oosterwijk JC; Jansen L; Mourits MJ Maturitas; 2010 Jul; 66(3):310-4. PubMed ID: 20409655 [TBL] [Abstract][Full Text] [Related]
20. Occult cancer of the fallopian tube in BRCA-1 germline mutation carriers at prophylactic oophorectomy: a case for recommending hysterectomy at surgical prophylaxis. Paley PJ; Swisher EM; Garcia RL; Agoff SN; Greer BE; Peters KL; Goff BA Gynecol Oncol; 2001 Feb; 80(2):176-80. PubMed ID: 11161856 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]